Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis

Journal of the National Cancer Institute

Volumn 106, Issue 6, 2014, Pages

  Templeton, Arnoud J ^a   McNamara, Mairéad G ^a   Šeruga, Boštjan ^b   Vera Badillo, Francisco E ^a   Aneja, Priya ^a   Ocaña, Alberto ^c   Leibowitz Amit, Raya ^a   Sonpavde, Guru ^d   Knox, Jennifer J ^a   Tran, Ben ^e   Tannock, Ian F ^a   Amir, Eitan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c Medical Oncology University Hospital   (Spain)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CLINICAL DECISION MAKING; DATA BASE; DISEASE FREE SURVIVAL; HUMAN; LYMPHOCYTE; META ANALYSIS; NEUTROPHIL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; REVIEW; SOLID TUMOR; SYSTEMATIC REVIEW; LYMPHOCYTE COUNT; MORTALITY; NEOPLASM; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

DISEASE-FREE SURVIVAL; HUMANS; LYMPHOCYTE COUNT; LYMPHOCYTES; NEOPLASMS; NEUTROPHILS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84905164478     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju124     Document Type: Review

References (135)

1. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-899.
2. O'Callaghan DS, O'Donnell D, O'Connell F, O'Byrne KJ. The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol. 2010;5(12):2024-2036.
3. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res. 2009;15(2):425-430.
4. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149-163.
5. Vigano A, Bruera E, Jhangri GS, et al. Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 2000;160(6):861-868.
6. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534-540.
7. Guthrie GJ, Charles KA, Roxburgh CS, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218-230.
8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100
9. Cochrane Handbook for Systematic Reviews of Interventions. http://www.cochrane.org/training/cochrane-handbook. Accessed November 20, 2013.
10. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, ed. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
12. Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2012;7(3):587-594.
13. Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J Immunol. 1985;134(1):230-234.
14. el-Hag A, Clark RA. Immunosuppression by activated human neu-trophils. Dependence on the myeloperoxidase system. J Immunol. 1987;139(7):2406-2413.
15. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860-867.
16. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93-103.
17. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113.
18. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-545.
19. Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58(1):58-64.
20. Kantola T, Klintrup K, Vayrynen J P, et al. Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma. Br J Cancer. 2012;107(10):1729-1736.
21. McCourt M, Wang JH, Sookhai S, Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg. 1999;134(12):1325-1331; discussion 1331-1322.
22. Di Carlo E, Forni G, Musiani P. Neutrophils in the antitumoral immune response. Chem Immunol Allergy. 2003;83:182-203.
23. McCourt M, Wang JH, Sookhai S, Redmond HP. Activated human neu-trophils release hepatocyte growth factor/scatter factor. Eur J Surg Oncol. 2001;27(4):396-403.
24. Jablonska E, Kiluk M, Markiewicz W, et al. TNF-alpha, IL-6 and their soluble receptor serum levels and secretion by neutrophils in cancer patients. Arch Immunol Ther Exp (Warsz). 2001;49(1):63-69.
25. Schaider H, Oka M, Bogenrieder T, et al. Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer. 2003;103(3):335-343.
26. Shamamian P, Schwartz JD, Pocock BJ, et al. Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol. 2001;189(2):197-206.
27. Scapini P, Nesi L, Morini M, et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol. 2002;168(11):5798-5804.
28. Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. Biol Pharm Bull. 2007;30(11):2001-2006.
29. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218-228.
30. Templeton AJ, Pezaro C, Omlin A, et al. New prognostic score for meta-static castration-resistant prostate cancer with incorporation of neutrophil to lymphocyte ratio. European Cancer Congress. September 27 to October 1; Amsterdam, Netherlands. 2013:abstract 1008.
31. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010;16(23):5805-5813.
32. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104(8):1288-1295.
33. Botta C, Mazzanti R, Guglielmo A, et al. Treatment-related changes in systemic inflammatory status, measured by neutrophil-to-lymphocyte ratio, is predictive of outcome in metastatic colorectal cancer patients. Eur J Cancer. 2011;47(9):S181.
34. Lee Y, Kim SH, Han J-Y, et al. Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. J Cancer Res Clin Oncol. 2012;138(12):2009-2016.
35. Leibowitz-Amit R, Templeton AJ, Atenafu EG, et al. Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC). J Clin Oncol. 2013;31(Supp l):abstract 5058.
36. Park YH, Lee YJ, Ku JH, Kwak C, Kim HH. Neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in patients with meta-static clear cell renal cell carcinoma receiving sunitinib as first-line therapy. J Urol. 2013;189(4):e787.
37. Azab B, Jaglall N, Atallah JP, et al. Neutrophil-lymphocyte ratio as a predictor of adverse outcomes of acute pancreatitis. Pancreatology. 2011;11(4):445-452.
38. Park JJ, Jang HJ, Oh IY, et al. Prognostic value of neutrophil to lymphocyte ratio in patients presenting with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013;111(5):636-642
39. An X, Ding PR, Li YH, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers. 2010;15(6):516-522.
40. Cima I, Schiess R, Wild P, et al. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer. Proc Natl Acad Sci USA. 2011;108(8):3342-3347.
41. Azab B, Shah N, Radbel J, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30(1):432.
42. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hema-tologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200(2):197-203.
43. Carruthers R, Tho LM, Brown J, et al. Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer. Colorectal Dis. 2012;14(10):e701-e707.
44. Cedres S, Torrejon D, Martinez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14(11):864-869.
45. Cetin B, Berk V, Kaplan MA, et al. Is the pretreatment neutrophil to lymphocyte ratio an important prognostic parameter in patients with meta-static renal cell carcinoma? Clin Genitourinary Cancer. 2013;11(2):141-148.
46. Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012;27(3):553-561.
47. Chiang SF, Hung HY, Tang R, et al. Can neutrophil-to-lymphocyte ratio predict the survival of colorectal cancer patients who have received curative surgery electively? Int J Colorectal Dis. 2012;27(10):1347-1357.
48. Cho H, Hur HW, Kim SW, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunology, Immunotherapy. 2009;58(1):15-23.
49. Chua W, Charles KA, Baracos VE, Clarke SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. 2011;104(8):1288-1295.
50. Chua W, Clarke SJ, Charles KA. Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Supportive Care Cancer. 2012;20(8):1869-1874.
51. Ding P-R, An X, Zhang R-X, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis. 2010;25(12):1427-1433.
52. Dutta S, Crumley ABC, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour-and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011;35(8):1861-1866.
53. Dutta S, Crumley ABC, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. Am J Surg. 2012;204(3):294-299.
54. Gomez D, Morris-Stiff G, Toogood GJ, Lodge JPA, Prasad KR. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol. 2008;97(6):513-518.
55. Gomez D, Morris-Stiff G, Wyatt J, et al. Surgical technique and systemic inflammation influences long-term disease-free survival following hepatic resection for colorectal metastasis. J Surg Oncol. 2008;98(5):371-376.
56. Gomez D, Farid S, Malik HZ, et al. Preoperative neutrophil-to-lympho-cyte ratio as a prognostic predictor after curative resection for hepatocel-lular carcinoma. World J Surg. 2008;32(8):1757-1762.
57. Gondo T, Nakashima J, Ohno Y, et al. Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology. 2012;79(5):1085-1091.
58. Guo ZX, Wei W, Zhong C, et al. Correlation of preoperative neutrophil-to-lymphocyte ratio to prognosis of young patients with hepatocellular carcinoma. Chinese J Cancer. 2009;28(11):75-80.
59. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colo-rectal liver metastases. Eur J Surg Oncol. 2008;34(1):55-60.
60. Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome following liver transplantation for hepato-cellular carcinoma (HCC). Am J Transplant. 2009;9(2):286.
61. He J-R, Shen G-P, Ren Z-F, et al. Pretreatment levels of peripheral neutro-phils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck. 2012;34(12):1769-1776.
62. Huang Z-L, Luo J, Chen M-S, Li J-Q, Shi M. Blood neutrophil-to-lym- phocyte ratio predicts survival in patients with unresectable hepatocellu-lar carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol. 2011;22(5):702-709.
63. Hung H-Y, Chen J-S, Yeh CY, et al. Effect of preoperative neutrophil-lymphocyte ratio on the surgical outcomes of stage II colon cancer patients who do not receive adjuvant chemotherapy. Int J Colorectal Dis. 2011;26(8):1059-1065.
64. Idowu OK, Ding Q, Taktak AFG, Chandrasekar CR, Yin Q. Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma. Biomarkers. 2012;17(6):539-544.
65. Jeong JH, Lim SM, Yun JY, et al. Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology (Switzerland). 2012;83(5):292-299.
66. Jung MR, Park YK, Jeong O, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts poor survival following resection in late stage gastric cancer. J Surg Oncol. 2011;104(5):504-510.
67. Kaneko M, Nozawa H, Sasaki K, et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy. Oncology (Switzerland). 2012;82(5):261-268.
68. Kao SCH, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010;16(23):5805-5813.
69. Kao SCH, Klebe S, Henderson DW, et al. Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumo-nectomy. J Thorac Oncol. 2011;6(11):1923-1929.
70. Kao SC, Vardy J, Chatfield M, et al. Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales dust diseases board. Clin Lung Cancer. 2013;14(1):70-77.
71. Keizman D, Gottfried M, Ish-Shalom M, et al. Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist. 2012;17(12):1508-1514.
72. Kim YH, Choi WJ. The effectiveness of postoperative neutrophils to lymphocytes ratio in predicting long-term recurrence after stomach cancer surgery. J Korean Surg Soc. 2012;83(6):352-359.
73. Kishi Y, Kopetz S, Chun YS, et al. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009;16(3):614-622.
74. Koh YW, Kang HJ, Park C, et al. Prognostic significance of the ratio of absolute neutrophil count to absolute lymphocyte count in classic Hodgkin lymphoma. AM J Clin Pathol. 2012;138(6):846-854.
75. Kunisaki C, Takahashi M, Ono HA, et al. Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy. Oncology (Switzerland). 2012;83(4):183-191.
76. Kwon H-C, Kim SH, Oh SY, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012;17(3):216-222.
77. Lee Y-Y, Choi CH, Kim H-J, et al. Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res. 2012;32(4):1555-1561.
78. Leitch EF, Chakrabarti M, Crozier JEM, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007;97(9):1266-1270.
79. Limaye AR, Cabrera R. Evaluation of the neutrophil-lymphocyte ratio as a predictor of survival after liver transplantation for hepatocellular carcinoma. J Clin Oncol. 2011;29(Suppl 4):abstract 170.
80. Liu H, Liu G, Bao Q, et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in rectal carcinoma. J Gastrointest Cancer. 2010;41(2):116-120.
81. Malik HZ, Prasad KR, Halazun KJ, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007;246(5):806-814.
82. Mallappa S, Sinha A, Gupta S, Chadwick SJD. Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis. 2013;15(3):323-328.
83. Miyata H, Yamasaki M, Kurokawa Y, et al. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med. 2011;2(5):879-885.
84. Mohri Y, Tanaka K, Ohi M, et al. Prognostic significance of host-and tumor-related factors in patients with gastric cancer. World J Surg. 2010;34(2):285-290.
85. Motomura T, Shirabe K, Mano Y, et al. Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58(1):58-64.
86. Neal C P, Mann CD, Sutton CD, et al. Evaluation of the prognostic value of systemic inflammation and socioeconomic deprivation in patients with resectable colorectal liver metastases. Eur J Cancer. 2009;45(1):56-64.
87. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 2010;184(3):873-878.
88. Ohno Y, Nakashima J, Ohori M, et al. Followup of neutrophil-to-lym- phocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol. 2012;187(2):411-417.
89. Ohno Y, Nakashima J, Ohori M, et al. Clinical variables for predicting met-astatic renal cell carcinoma patients who might not benefit from cytore-ductive nephrectomy: neutrophil-to-lymphocyte ratio and performance status. Int J Clin Oncol. 2014;19(1):139-145.
90. Perez DR, Baser RE, Cavnar MJ, et al. Blood neutrophil-to-lymphocyte ratio is prognostic in gastrointestinal stromal tumor. Ann Surg Oncol. 2013;20(2):593-599.
91. Perisanidis C, Kornek G, Poschl PW, et al. High neutrophil-to-lympho-cyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer. Med Oncol. 2013;30(1):334.
92. Pinato DJ, Mauri FA, Ramakrishnan R, et al. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2012;7(3):587-594.
93. Pinato DJ, Stebbing J, Ishizuka M, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57(5):1013-1020.
94. Proctor MJ, McMillan DC, Morrison DS, et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer. 2012;107(4):695-699.
95. Sarraf KM, Belcher E, Raevsky E, et al. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137(2):425-428.
96. Sharaiha RZ, Halazun KJ, Mirza F, et al. Elevated preoperative neutro-phil: lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. Ann Surg Oncol. 2011;18(12):3362-3369.
97. Shimada H, Takiguchi N, Kainuma O, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer. 2010;13(3):170-176.
98. Shouyu W, Zhen Z, Fang F, et al. The neutrophil/lymphocyte ratio is an independent prognostic indicator in patients with bone metastasis. Oncol Lett. 2011;2(4):735-740.
99. Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197(4):466-472.
100. Sonpavde G, Pond GR, Clarke SJ, et al. Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial. J Clin Oncol. 2012;30(Suppl):abstract 4644.
101. Teramukai S, Kitano T, Kishida Y, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 2009;45(11):1950-1958.
102. Tomita M, Shimizu T, Ayabe T, Onitsuka T. Elevated preoperative inflammatory markers based on, neutrophil-to-lymphocyteratio and C-reactive protein predict poor survival in resected non-small cell lung cancer. Anticancer Res. 2012;32(8):3535-3538.
103. Ubukata H, Konishi S, Nakachi T, et al. Characteristics of the serum pep-sinogen (Pg) test, and the relationship between Pg test results and gastric cancer outcomes. Scand J Surg. 2010;99(4):201-207.
104. Wang GY, Yang Y, Li H, et al. A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation. PLoS One. 2011;6(9):e25295.
105. Wang D-S, Luo H-Y, Qiu M-Z, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012;29(5):3092-3100.
106. Wang D-S, Ren C, Qiu M-Z, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol. 2012;33(3):749-756.
107. Yamanaka T, Matsumoto S, Teramukai S, et al. The baseline ratio of neu-trophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007;73(3-4):215-220.
108. Yao Y, Yuan D, Liu H, Gu X, Song Y. Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother. 2013;62(3):471-479.
109. Zhang Y, Peng Z, Chen M, et al. Elevated neutrophil to lymphocyte ratio might predict poor prognosis for colorectal liver metastasis after percutaneous radiofrequency ablation. Int J Hyperthermia. 2012;28(2):132-140.
110. Dumitrascu T, Chirita D, Ionescu M, Popescu I. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg. 2013;17(5):913-924.
111. Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158.
112. Kobayashi M, Kubo T, Komatsu K, et al. Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy. Med Oncol. 2013;30(2):556.
113. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013;16(1):55-59.
114. Oh BS, Jang JW, Kwon JH, et al. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:78.
115. Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer. 2013;108(4):901-907.
116. Szkandera J, Absenger G, Liegl-Atzwanger B, et al. Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br J Cancer. 2013;108(8):1677-1683.
117. Azab B, Bhatt VR, Phookan J, et al. Usefulness of the neutrophil-to-lym-phocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217-224.
118. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011;13(7):499-503.
119. Bambury RM, Teo MY, Yusuf A, et al. The association of pretreatment neu-trophil to lymphocyte ratio with overall survival in patients with glioblas-toma multiforme (GBM). J Clin Oncol. 2012;30(Suppl):abstract 2062.
120. Berger R, Keizman D, Ish-Shalom M, et al. Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su). J Clin Oncol. 2012;30(Suppl):a bstract e15058.
121. Botta C, Mazzanti R, Cusi MG, et al. Baseline inflammatory status defined by neutrophil to lymphocyte cell count ratio (NLR) predicts progression free survival (PFS) in metastatic colorectal cancer patients (mCRC) undergoing bevacizumab based biochemotherapy. Eur J Cancer. 2011;47 (Suppl):S174-S175.
122. Chen Z-Y, Lieu CH, Jiang Z-Q, et al. Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer. J Clin Oncol. 2012;30(Suppl):abstract 3598.
123. Harji D, Griffiths B, Sarveswaran J, et al. Neutrophil-lymphocyte ratio as a predictor of survival in locally recurrent rectal cancer. European Society of Coloproctology Annual Meeting; September 26-28, 2012. Abs OP20; Vienna, Austria.
124. Huang P, Carducci MA, Eisenberger MA, et al. The association of pre-treatment (pre-tx) neutrophil to lymphocyte ratio (NLR) with outcome of sunitinib tx in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2011;29(Suppl):abstract 4621.
125. Kim S, Lee H, Baek J. Predictors of survival in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2011;29(Suppl 4):abstract 583.
126. Krane LS, Richards KA, Manny T, Kader AK, Hemal AK. Preoperative neu-trophil lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. J Endourol. 2013;27(8):1046-1050.
127. Lee S, Oh SY, Kwon H-C, et al. The clinical significance of neutrophil-lymphocyte ratio versus platelet-lymphocyte ratio in patients with meta-static gastric cancer. J Clin Oncol. 2012;30(Suppl):abstract e14686.
128. Mohamed Z, Pinato DJ, Sharm R. Novel inflammation-based prognostic determinants in patients with carcinoma of unknown primary. European Society of Medical Oncology Congress; September 28 to October 2; Vienna, Austria. 2012;abstract 1169P.
129. Sella A, Ish-Shalom M, Maimon N, et al. Pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with ketoconazole (keto): Association with outcome and predictive model. J Clin Oncol. 2012;30(Suppl):abstract 4564
130. To h EW, Botterill I, Wilson J, Sebag-Montefiore D. Neutrophil-lymphocyte ratio (NLR) as a simple and novel biomaker in predicting locoregional recurrence after chemoradiotherapy for squamous cell carcinoma (SCC) of the anus. Colorectal Dis. 2014;16(3):O90-97.
131. Cedres Perez S, Montero MA, Torrejon D, et al. PI3K pathway and downstream signaling analysis in malignant pleural mesothelioma (MPM). J Clin Oncol. 2011;29(Suppl):abstract 7057.
132. De Vincenzo F, Rossoni G, Santoro A, et al. NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM). J Clin Oncol. 2011;29(Suppl):abstract 7089.
133. McNamara MG, Templeton AJ, Maganti M, et al. Neutrophil/lymphocyte ratio (NLR) as a prognostic factor in biliary tract cancer (BTC). J Clin Oncol. 2013;31(Suppl):abstract 4130.
134. Pass HI, Donington JS, Gadgeel SM, et al. Plasma osteopontin and the prognosis of pleural mesothelioma. J Clin Oncol. 2013;31(Suppl):abstract 11109.
135. Tran B, Wong H, Desai J, et al. Can systemic inflammation at diagnosis predict benefit from primary resection in metastatic colorectal cancer (mCRC)? J Clin Oncol. 2012;30(Suppl 34):abstract 410.